Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics

Journal of Pathology

Volumn 210, Issue 2, 2006, Pages 163-171

  Booman, M ^a   Douwes, J ^a   Glas, A M ^b   de Jong, D ^c   Schuuring, E ^a   Kluin, P M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Agendia NV   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Activated B cell like subtype; Diffuse large B cell lymphoma; Gene expression analysis; Immune privileged site; Immunohistochemistry; Somatic hypermutation

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN BCL 6; PROTEIN MUM1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; TESTIS CANCER;

B-LYMPHOCYTES; CLUSTER ANALYSIS; DNA, COMPLEMENTARY; DNA, NEOPLASM; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; INTERFERON REGULATORY FACTORS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; NEOPLASM PROTEINS; NEPRILYSIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; TESTICULAR NEOPLASMS;

EID: 33749043017     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2033     Document Type: Article

References (56)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
2. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lympboma. N Engl J Med 2002;346:1937-1947.
3. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 2002;8:68-74.
4. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
5. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
6. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-470.
7. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, et al. Germinal center phenotype and bc1-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99-1136-1143.
8. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005;23:7060-7068.
9. Berglund M. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113-1120.
10. Stevenson F, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, et al. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998;162:247-259.
11. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 2000;97:10209-10213.
12. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypernimation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
13. Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. Leukemia 2004;18:1775-1779,
14. Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, et al. Expression of the AID protein in normal and neoplastic B-cells. Blood 2004;104:3318-3325.
15. Smit LA, Bende RJ, Aten J, Guikema JEJ, Aarts WM, van Noesel CJM. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 2003;63:3894-3898.
16. Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000;88:154-161.
17. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma. of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003;21:20-27.
18. Schlegel U, Schmidt-Wolf IGH, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000;181:1-12.
19. Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105:301-307.
20. Weigelt B, Glas AM, Wessels LFA, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901-15905.
21. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15-Y.
22. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, et al. Functional discovery via a compendium of expression profiles. Cell 2000;102:109-126.
23. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-9996.
24. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-208.
25. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121.
26. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-2317.
27. Giudicelli V, Chaume D, Lefranc MP. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 2004;32:W435-W440.
28. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003;31:3497-3500.
29. Lossos IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000;95:1797-1803.
30. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004;103:1869-1875.
31. Guikema JE, Rosati S, Akkermans K, Bende RJ, van Noesel CJ, Van Krieken JH, et al. Quantitative RT-PCR analysis of activation-induced cytidine deaminase expression in tissue samples from mantle cell lymphoma and B-cell chronic lymphocytic leukemia patients. Blood 2005;105:2997-2998.
32. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005;11: 1065-1072.
33. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma patients with poor outcome. Blood 2004;104:2933-2935.
34. Hasselblom S, Ridell B, Wedel H, Norrby K, Sender BM, Ekman T. Testicular lymphoma - a retrospective, population-based, clinical and imnumohistochemical study. Acta Oncol 2004;43:758-765.
35. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569-3577.
36. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002;35:38-48.
37. Booman M, Douwes J, Glas AM, Riemersma SA, Jordanova ES, Kok K, et al. Mechanisms and effects of loss of HLA class II expression in immune privileged site-associated B-cell lymphoma. Clin Cancer Res 2006;12:2698-2705.
38. Boonstra. R, Koning A, Mastik M, van den BA, Poppema S. Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch 2003;443:164-169.
39. Montesinos-Rongen M, Zuhlke-Jenisch R, Gesk S, Martin-Subero JI, Schaller C, Van Roost D, et al. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 2002;61:926-933.
40. Lambrechts AC, Looijenga LH, van't Veer MB, van Echten J, Timens W, Oosterhuis JW. Lymphomas with testicular localisation show a consistent BCL-2 expression without a translocation (14;18): a molecular and immunohistochemical study. Br J Cancer 1995;71:73-77.
41. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2005;107:190-196.
42. Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998;162:261-280.
43. Nakamura N, Kuze T, Hashimoto Y, Tasaki K, Hojo H, Sasaki Y, et al. Analysis of the immunoglobulin heavy chain gene variable region of 101 cases with peripheral B cell neoplasms and B cell chronic lymphocytic leukemia in the Japanese population. Pathol Int 1999;49:595-600.
44. Hyland J, Lasota J, Jasinski M, Petersen RO, Nordling S, Miettinen M. Molecular pathological analysis of testicular diffuse large cell lymphomas. Hum Pathol 1998;29:1231-1239.
45. Montesinos-Rongen M, Kuppers R, Schluter D, Spieker T, Van Roost D, Schaller C, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999;155:2077-2086.
46. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 1999;94:1738-1746.
47. Endo S, Zhang SJ, Saito T, Kouno M, Kuroiwa T, Washiyama K, et al. Primary malignant lymphoma of the brain: mutation pattern of rearranged immunoglobulin heavy chain gene. Jpn J Cancer Res 2002;93:1308-1316.
48. Pasqualucci L, Neurneister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple protooncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-346.
49. Finn LS, Viswanatha DS, Belasco JB, Snyder H, Huebner D, Sorbara L, et al. Primary follicular lymphoma of the testis in childhood. Cancer 1999;85:1626-1635.
50. Pileri SA, Sabattini E, Rosito P, Zinzani PL, Ascani S, Fraternali-Orcioni G, et al. Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. J Clin Pathol 2002;55:684-688.
51. Heller KN, Teruya-Feldstein J, La Quaglia MP, Wexler LH. Primary follicular lymphoma of the testis: excellent outcome following surgical resection without adjuvant chemotherapy. J Pediatr Hematol Oncol 2004;26:104-107.
52. Montesinos-Rongen M, Schmitz R, Courts C, Stenzel W, Bechtel D, Niedobitek G, et al. Absence of inummoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 2005; 166:1773 -1779.
53. Gonda H, Sugai M, Nambu Y, Katakai T, Agata Y, Mori KJ, et al. The balance between Pax5 and Id2 activities is the key to AID gene expression. J Exp Med 2003;198:1427-1437.
54. Sayegh CE, Quong MW, Agata Y, Murre C. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nature Immunol 2003;4:586-593.
55. Zhou C, Saxon A, Zhang K. Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification. J Immunol 2003;170:1887-1893.
56. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 2002;195:1003-1012.